BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28

• 

  Does CRISPR Have a Bias Problem?

  Recent scientific papers report errors in CRISPR gene editing linked to ancestry.

  February 2, 2023

   · 

  3 min read

   · 

  Gail Dutton
• 

  Drug Development

  Roche Abandons AKT Prostate Cancer Asset

  Roche is dropping its investigational AKT inhibitor ipatasertib, which was being assessed in a Phase III trial for castration-resistant prostate cancer, as well as several other candidates.

  February 2, 2023

   · 

  2 min read

   · 

  Tristan Manalac
• 

  What to Do When You’re Given Tasks Above Your Experience Level

  To help you take on any task you’re given at work, BioSpace has provided a guide detailing what to do when you’re asked to do things above your experience level.

  February 2, 2023

   · 

  3 min read

   · 

  Franklin Carpenter
• 

  Deals

  Karuna Plucks Goldfinch’s TRPC4/5 Assets for Anxiety, Mood Disorders

  Karuna Therapeutics acquired exclusive rights to Goldfinch Bio’s investigational TRPC4/5 channel candidates in a deal potentially worth $520 million.

  February 2, 2023

   · 

  2 min read

   · 

  Hayley Shasteen
• 

  FDA

  GSK Wins Approval for CKD Anemia Drug – with Conditions

  Wednesday, the FDA approved GSK’s daprodustat, now to be marketed as Jesduvroq, for the treatment of anemia due to chronic kidney disease in adult patients.

  February 2, 2023

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Patient Square Touts Record-Breaking $3.9B Inaugural Fund

  Patient Square Capital announced a record-breaking inaugural fund totaling $3.9 billion, proving even in an unstable economy, there’s still money to be made.

  February 2, 2023

   · 

  1 min read

   · 

  Kate Goodwin
• Sequana Medical Notice of 2022 Full Year Results and Business Update

  Sequana Medical NV, a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, will announce its full year results ended 31 December 2022 on Thursday, 9 February 2023.

  February 2, 2023

   · 

  3 min read
• Drug Development

  SONIRE Announces First Patient Enrolled in Randomized Phase 2 Study of Its Novel HIFU Therapy System for Unresectable Pancreatic Cancer Patients in Japan

  SONIRE Therapeutics Inc., based in Tokyo, announces that it has commenced a randomized phase 2 study for the treatment of unresectable pancreatic cancer with SONIRE’s next-generation High-Intensity Focused Ultrasound therapy system.

  February 2, 2023

   · 

  2 min read
• Business

  Takeda Reinforces Long-term Growth Through Pipeline Advancement and Two Targeted Acquisitions; Delivers Another Strong Quarter in FY2022 Q3

  Takeda announced financial results for the third quarter of fiscal year 2022.

  February 2, 2023

   · 

  17 min read
• Business

  BerGenBio Announces the Establishment of Oncology Scientific Advisory Board

  BerGenBio ASA announced the formation of a scientific advisory board consisting of four world-renowned non-small cell lung cancer experts from top oncology centers around the globe to enhance the development of bemcentinib for the treatment of NSCLC patients with STK11 mutations.

  February 2, 2023

   · 

  5 min read